Cinacalcet and achievement of the NKF/K-DOQITM recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study
Authors:
- P. UrenaPUP. Urena
- S. H. JacobsonSJS. H. Jacobson
- E. ZittEZE. Zitt
- M. VervloetMVM. Vervloet
- F. MalbertiFMF. Malberti
- N. AshmanNAN. Ashman
- S. LeaveySLS. Leavey
- M. RixMRM. Rix
- I. OsIOI. Os
- H. SahaHSH. Saha
- M. RybaMRM. Ryba
- V. BencovaVBV. Bencova
- 15 April 2009
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 24 (9) , 2852-2859
Abstract
The use and effectiveness of cinacalcet in 'real-world' clinical practice was investigated in a pan-European observational study in dialysis patients with secondary hyperparathyroidism (SHPT) of varying severity. Adult patients with chronic kidney disease on dialysis who had initiated cinacalcet treatment were enrolled. Data were collected 6 months before initiating cinacalcet, at baseline (initiation of cinacalcet) and up to 12 months after cinacalcet initiation. A total of 1865 patients [mean (SD) age 58 (15) years] were enrolled from 187 sites in 12 countries. Most patients had a dialysis vintage of > or =1 year (1-5 years, n = 833; >5 years, n = 748 versus <1 year, n = 265). The patients generally had severely uncontrolled intact parathyroid hormone (iPTH) serum levels (median 721 pg/ml) and elevated phosphorus (median 5.9 mg/dl) and calcium (median 9.6 mg/dl) at baseline, despite being prescribed conventional therapies. The proportions of patients achieving the recommended [NKF-K/DOQI(TM) (KDOQI(TM))] targets increased from baseline [4%, 39%, 40% and 46% for iPTH, phosphorus, calcium and calcium-phosphorus product (Ca x P), respectively] to Month 12 (28%, 48%, 51% and 68%, respectively). At Month 12, 18% of patients had achieved the combined target for iPTH + Ca x P compared with 2% at baseline. Most patients (65%) received <60 mg/day cinacalcet at Month 12. Vitamin D sterol use remained fairly stable throughout the study. There was a 13% decrease in prescribed sevelamer; use of calcium-based phosphate binders increased by 5.6%. There was no unexpected safety or tolerability concerns. This analysis of current European clinical practice shows that-consistent with findings from randomized controlled trials and retrospective observational studies-cinacalcet improves attainment of KDOQI bone metabolism targets in dialysis patients with various stages of SHPT.Keywords
This publication has 20 references indexed in Scilit:
- Consistent Control of Mineral and Bone Disorder in Incident Hemodialysis PatientsClinical Journal of the American Society of Nephrology, 2008
- Postprandial Mineral Metabolism and Secondary Hyperparathyroidism in Early CKDJournal of the American Society of Nephrology, 2008
- Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE studyNephrology Dialysis Transplantation, 2008
- Mineral Metabolism, Mortality, and Morbidity in Maintenance HemodialysisJournal of the American Society of Nephrology, 2004
- Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving HemodialysisNew England Journal of Medicine, 2004
- Management of Secondary Hyperparathyroidism: The Importance and the Challenge of Controlling Parathyroid Hormone Levels without Elevating Calcium, Phosphorus, and Calcium-Phosphorus ProductAmerican Journal of Nephrology, 2003
- Re-evaluating our approach to calcium and phosphorus management in dialysis patientsAmerican Journal of Kidney Diseases, 2001
- Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal diseaseKidney International, 1999
- Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national studyAmerican Journal of Kidney Diseases, 1998
- Calcimimetics with potent and selective activity on the parathyroid calcium receptorProceedings of the National Academy of Sciences, 1998